Bristol-Myers Squibb discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products around the world. We offer products for hematology, oncology, cardiovascular, immunology, fibrotic and neuroscience diseases. The company’s products include Eliquis for stroke/systemic embolism risk reduction in non-valvular atrial fibrillation and treatment of DVT/PE. Opdivo is indicated for various anti-cancer indications including bladder cancer, blood cancer, colorectal cancer, head and neck cancer, RCC, HCC, lung cancer, melanoma, MPM, gastric cancer, and esophageal cancer. Pomalyst/Imnovid for multiple myeloma. Orencia for active rheumatoid arthritis and psoriatic arthritis. Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. Yervoy is also offered for the treatment of patients with unresectable or metastatic melanoma. Emplicity for the treatment of multiple myeloma. Abecma in the treatment of relapsed or refractory multiple myeloma. Lebrozil for the treatment of anemia. Opdurag for the treatment of unresectable or metastatic melanoma. Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma. Onureg for AML treatment. Inrevic for the treatment of myelofibrosis. Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptoms. Sotyktu for the treatment of moderate to severe plaque psoriasis. Augtiro is used to treat locally advanced or metastatic ROS1-positive NSCLC. Revlimid, an oral immunomodulator for the treatment of multiple myeloma. Abraxane is used to treat breast cancer, NSCLC, and pancreatic cancer. We sell our products to wholesalers, distributors, pharmacies, retail stores, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
www.bms.com
Source link
